The role of S100A1 in external auditory canal cholesteatoma

RAMIN NAIM and KARL HORMANN
Department of Otolaryngology, Head and Neck Surgery, University Hospital Mannheim, Germany

Received April 14, 2006; Accepted May 16, 2006

Abstract. S100 proteins were reported to be involved in different biological activities such as transduction of intracellular calcium signalling. It has been reported that each member of the S100 protein family exhibits a distinct tissue-specific pattern of expression. Furthermore, altered S100 protein expression and function correlate with many diseases. The expression of S100A1 was reported to be increased in different tissue with hyperplasia. The external auditory canal cholesteatoma (EACC) is a benign hyperplasia of the auditory meatal skin. However, without treatment, EACC destroys adjacent tissue. Seventeen EACC specimens were collected and investigated immunohistochemically against S100A1. Normal auditory meatal skin served as control. In the EACC, S100A1 showed a more homogeneous staining pattern, positively expressed throughout the epithelial layers. The keratin debris showed no detectable expression of S100A1. In the auditory meatal skin (control), S100A1 was only expressed in the basal layer of the epithelium. We showed that there are different staining patterns in normal auditory meatal skin, middle ear cholesteatoma and external auditory canal cholesteatomas. The immunoreactivity increased with the stage of the disease. Contrary to that reported previously in the middle ear cholesteatomas, the reactivity was strongest in the upper epithelial layers. In our collective, the epithelial matrix of the EACC showed strong reactivity throughout all the layers. Surprisingly, there is no study regarding the connection between growth factors and S100A1. In previous experiments we showed significant increase of growth factors in EACC. This correlates with our new data concerning S100A1. This is the first study to show the different reactivity pattern of S100A1 in the external auditory canal cholesteatoma.

Introduction

The S100 proteins were discovered in 1965 as a brain protein fraction. They were shown to consist of two different closely related molecules, S100a and S100b (1). The S100 protein family constitutes with its 19 known members the largest subgroup of the EF-hand calcium-binding proteins. At least 13 S100 genes are clustered on human chromosome 1q21, with the resultant designations running from S100A1 to S100A13 (2). S100A1 binds calcium via EF-hand calcium-binding motifs and undergoes a conformational change that exposes a hydrophobic patch (3). This hydrophobic patch allows calcium receptor proteins, including S100A1, to interact with hydrophobic resins such as phenyl-sepharose, a property which is utilized in the purification of these proteins. If the hydrophobic patch is a major contributor to interaction with calcium-dependent target proteins, then its unavailability in the absence of calcium suggests that calcium-independent target proteins will utilize a different mechanism to interact with S100A1 (3). S100A1 is preferentially expressed in muscle, especially in myocardial tissue. It is present in the cytosol and found associated with the SR and contractile filaments. A number of observations indicate that S100A1 is a major regulator of cardiac contractility (4). However, S100A1 has been reported to be expressed in human tumors (5). Furthermore, Pelc et al showed that middle ear cholesteatomas also presented distinct reactivity to S100A1. They concluded that in contrast to S100B, the expression of S100A1, S100A2, S100A4 and S100A5 are often present in epidermoid cysts, branchial cysts, craniopharyngiomas and middle ear cholesteatomas. S100A3 and S100A6 (and, to a lesser extent, S100A5) were most differentially expressed across the different histopathological groups analysed (6). In the field of Otolaryngology, the external auditory canal cholesteatoma (EACC) is a very rare pathological entity (7). The EACC is usually found in the inferior or posterior part of the bony external ear canal, and it is characterized by permanent growth of the epithelial tissue (Fig. 1a and b) (8). Establishing the cholesteatoma, the epithelial layer is the so-called matrix, and the adjacent subepithelial tissue is called perimatrix. The matrix contains hyperplastic epithelial tissue which destructively, tends to grow into adjacent anatomical structures such as the bony canal and mastoid cells in contrast to keratosis obturans (9). Treatment of choice remains total surgical removal of the chronic inflammatory tissue (10). Some authors maintain post-operative, post-traumatic, post-inflammatory disorders as etiologic factors for EACC (11). Other authors claim circulatory disorders of local vessels supplying the epidermal layer of the tympanic membrane and the auditory canal as the etiologic factor for...
disturbed epithelial migration in the area of the external auditory canal (10). We found that the angiogenic factors hepatocyte growth factor/scatter factor (HGF/SF), the tyrosine-kinase c-Met receptor, and vascular endothelial growth factor (VEGF) are all strongly expressed in the specimens of EACC (12). In comparison to keratinocyte culture, an in vitro study showed a higher baseline concentration of VEGF in the cholesteatoma cell culture (1.5- to 2-fold). Furthermore, stimulation of the cholesteatoma cells with HGF/SF resulted in a strong proliferation rate and increased release of VEGF (13).

The aim of this study was to investigate expression patterns of S100A1 protein in the EACC. Based on these results, we believe that S100A1 expression should be added into the panel of molecular markers for distinguishing EACC from different types of middle ear cholesteatomas.

Materials and methods

Collection of specimens. Between April 2000 and January 2005, 17 EACC specimens were collected from 17 patients undergoing surgery at the Department of Otorhinolaryngology of the University of Mannheim (normal auditory canal skin served as control tissue). The collected tissue was immediately fixed in formalin and embedded in paraffin. Two oto-laryngologists evaluated the specimens after hematoxylin and eosin staining. In each patient, the clinical data were reviewed in respect to age, sex, race, presenting symptom, side of the lesion and localization of the EACC (Tables I and II). The age of the patients ranged from 23 to 74 at the time of diagnosis (average age 50, median age 48). Except for one young patient (23 years), the patients in this study were elderly. Eleven patients were female and six were male. The patients were asked to describe their pain by characterizing the pain between 0 and 10 (0, no pain; 10, severe pain). In one case presenting stage IV EACC a high resolution temporal bone CT was performed. The patients were evaluated 4 and 8 weeks after surgery.

Immunohistochemical staining. Immunohistochemistry for S100A1 detection was performed by using a streptavidin-biotin complex procedure. Endogenous peroxidase was
Table I. Histology and staging.

<table>
<thead>
<tr>
<th>EACC no.</th>
<th>Epithelial hyperplasia</th>
<th>Keratin debris</th>
<th>Excavation</th>
<th>Periosteitis</th>
<th>Bony erosion</th>
<th>Bony sequester</th>
<th>Infiltration of adjacent tissue</th>
<th>Stage</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>2</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td>III</td>
</tr>
<tr>
<td>3</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>4</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>5</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>6</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td>Mastoid</td>
<td>IV</td>
</tr>
<tr>
<td>7</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>8</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td>III</td>
</tr>
<tr>
<td>9</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td>III</td>
</tr>
<tr>
<td>10</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>11</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td>III</td>
</tr>
<tr>
<td>12</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I</td>
</tr>
<tr>
<td>13</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I</td>
</tr>
<tr>
<td>14</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>15</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>II</td>
</tr>
<tr>
<td>16</td>
<td>x</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>I</td>
</tr>
<tr>
<td>17</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td>x</td>
<td></td>
<td></td>
<td>III</td>
</tr>
</tbody>
</table>

Table II. Patient characteristics.

<table>
<thead>
<tr>
<th>EACC no.</th>
<th>Age</th>
<th>Gender</th>
<th>Pain</th>
<th>Otorrhea</th>
<th>Loss of hearing</th>
<th>Side</th>
<th>Location in the auditory canal</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>37</td>
<td>F</td>
<td>43</td>
<td>+</td>
<td>-</td>
<td>L</td>
<td>Superior (between 10-1 o'clock)</td>
</tr>
<tr>
<td>2</td>
<td>34</td>
<td>F</td>
<td>65</td>
<td>+</td>
<td>-</td>
<td>L</td>
<td>Anterior (between 1-4 o'clock)</td>
</tr>
<tr>
<td>3</td>
<td>45</td>
<td>M</td>
<td>64</td>
<td>+</td>
<td>-</td>
<td>L</td>
<td>Inferior (between 4-7 o'clock)</td>
</tr>
<tr>
<td>4</td>
<td>23</td>
<td>M</td>
<td>56</td>
<td>-</td>
<td>-</td>
<td>L</td>
<td>Anterior inferior</td>
</tr>
<tr>
<td>5</td>
<td>68</td>
<td>F</td>
<td>64</td>
<td>-</td>
<td>-</td>
<td>L</td>
<td>Middle</td>
</tr>
<tr>
<td>6</td>
<td>74</td>
<td>M</td>
<td>0</td>
<td>-</td>
<td>-</td>
<td>L</td>
<td>Posterior inferior</td>
</tr>
<tr>
<td>7</td>
<td>53</td>
<td>F</td>
<td>46</td>
<td>-</td>
<td>-</td>
<td>L</td>
<td>Posterior (between 7-10 o'clock)</td>
</tr>
</tbody>
</table>

*No pain, 0; strong pain, 10. *R, right; L, left.

blocked with 0.3% hydrogen peroxide for 30 min. Sections were washed with phosphate-buffered saline (PBS) and incubated with normal sheep serum in PBS for 30 min at room temperature to block non-specific antibody reactions. The sections were then incubated overnight at 4°C with the primary anti-body [S100A1 (C20), sc #7849, Santa Cruz, Heidelberg, Germany]. The slides were washed in several changes of PBS. The sections were then incubated with a peroxidase-conjugated secondary antibody (Dako, Hamburg, Germany). After being washed twice in PBS, sections were
treated with a streptavidin-biotin-peroxidase complex and
peroxidase reaction was performed using aminoethyl-
encarbazol (AEC) (Dako) as chromogen. The different
antibodies were diluted to the desired concentrations in PBS.
Bright field microscopy was used to analyse the cells and
was performed using a Zeiss Axioskop microscope.
Epithelial tumor tissues and normal auditory meatal skin
served as positive controls. The degree of immunohisto-
chemical staining was evaluated semi-quantitatively by two
examiners separately. To describe the slides the stain-
intensity was evaluated (strong, >80% positive cells; 
moderate, 50-80% positive cells; week, <50% positive cells; 
and no positive cells).

Results

In the auditory meatal skin (control), S100A1 was expressed
in the basal layer of the epithelium (Fig. 1c). The expression
was predominantly located in the cytoplasm of the cells. The
expression of S100A1 decreased towards the surface of the
normal epithelium (Fig. 1c). The keratin debris showed no
detectable expression of S100A1. In the EACC, S100A1
showed a more homogenous staining pattern, positively
expressed throughout the epithelial layers (Fig. 1d). The
perimatrix of all the specimens also showed faint to moderate
positive staining. One specimen showed no staining of the
apical part of the epithelium. This was diagnosed at an early
stage of disease without excavation of the epitheli um and
adjacent periestitis of the bony canal. The keratin debris of
the EACC specimens showed no staining (Fig. 1d). The
immunoreactive status of the basal membrane was strongly
reactive in the EACC, however, in the normal tissue the
reactivity was weak.

Discussion

In this study we showed that obviously there are different
staining patterns in normal auditory meatal skin, middle ear
cholesteatoma and external auditory canal cholesteatomas.
The absent reactivity against S100A1 in the keratin layer is
common among the different types of the entities. The apical
keratin layer is comprised of dead cells with no intracellular
signalling. There is increasing evidence that S100 proteins
play an important part in calcium signalling pathways, and
that each member of the S100 protein family exhibits a
distinct tissue-specific pattern of expression (2). However,
the epithelial part of the different specimens showed different
expression of S100A1. The EACC matrix showed strong
reactivity against S100A1 (Fig. 1d). The immunoreactivity
increased with the stage of the disease (Table I). The normal
auditory meatal skin showed strong reactivity in the basal
layers. The apical epithelial part showed faint to no immuno-
staining against S100A1 (Fig. 1c).

Pecl et al compared different benign epithelial tissue of
the head and neck and stated that from a clinical point of view,
epidermoid and branchial cysts are benign and non-aggressive
lesions, in contrast to craniopharyngiomas and cholesteatomas,
which are more aggressive and have a strong potential to
recur and invade the surrounding tissue. They reported that in
all cases, the acquired middle ear cholesteatomas showed the
strongest positive staining of the different epithelial layers. In
the cholesteatomas, the reactivity was strongest in the upper
epithelial layers. The basal membrane was less positive (6).
In our collective, the epithelial matrix of the EACC showed
strong reactivity throughout all the layers. The basal membrane
was also moderate to strongly reactive. This emphasizes the
hypothesis that the level of positive reactivity against S100A1
is somehow linked to the degree of aggressiveness of the
investigated tissue. The S100 proteins have become of major
interest because of their differential expression in neoplastic
tissues, their involvement in metastatic processes, and the
clustered organization of at least 10 S100 genes on human
chromosome 1q21, a region frequently rearranged in several
tumors. Ilg et al reported that S100 is expressed in human
tumors (5). Several authors reported that renal cell
 carcinos showed significant immunoreactivity against
S100A1. However, there was no significant correlation
between the mutant p53 and S100A1. S100A1 was suggested
to serve as a marker in judging the degree of malignancy and
invasion of renal cell carcinomas (14). Surprisingly, there is
no study regarding the connection between growth factors
(VEGF, FGF-2, HGF, c-Met etc.) and S100A1. In previous
experiments we showed significant increase of growth
factors in EACC (in vitro and in vivo). This correlates with
our new data concerning S100A1. While these previous
studies suggest that S100A1 antagonists would be valuable in
adjunct therapy in the treatment of some diseases, there is no
information available regarding the target proteins with
which S100A1 interacts to regulate cell proliferation or
toxicity, nor have the molecular mechanisms of S100A1-
target protein interactions been ascertained. Both of these
pieces of information are essential for the rational design of
S100A1 antagonists.

In future, it is necessary to study the role of S100 proteins
in different epithelial malignancies and their role in angio-
genesis, growth and invasiveness of these tissues. This is the
first study to show the different reactivity pattern of S100A1
in the external auditory canal cholesteatoma.

Reference

1. Moore B: A soluble protein characteristic of the nervous system.
2. Schäfer B and Heizmann C: The S100 family of EF-hand
calcium-binding proteins: functions and pathology. Trends
3. Zimmer DB, Cornwell EH, Landar A and Song W: The S100
protein family: history, function and expression. Brain Res Bull
4. Most P, Bernotat J, Ehlermann P, Pleger ST, Reppel M,
Borries M, Niroomand F, Pieske B, Janssen PM, Eschenhagen T,
Karczewski P, Smith GL, Koch WJ, Katus HA and Remppis A:
S100A1: a regulator of myocardial contractility. Proc Natl Acad
5. Ilg EC, Schäfer BW and Heizmann CW: Expression pattern of
S100 calcium-binding proteins in human tumors. Int J Cancer
Salmon I, Kiss R, Louryan S and Decaestecker C: Differential
expression of 10 calcium-binding proteins in epidermoid
cysts, branchial cysts, craniopharyngiomas and cholesteatomas.
of the month: external auditory canal cholesteatoma. Otol
8. Holt JJ: Ear canal cholesteatoma. Laryngoscope 102: 608-613,